Physical/Mental Wellness

The Malaria Headline Is the Baby Drug. The Bigger Story Is the Test That Finds What the Old Test Misses.

The infant formulation closes a lethal dosing gap; the HRP2-deletion-aware diagnostics protect the whole malaria-control stack.

By I F · 3 min read

TL;DR

WHO has prequalified the first antimalarial formulation designed for newborns and young infants weighing 2–5 kg: artemether-lumefantrine, sold by Novartis as Coartem Baby / Riamet Baby.
The same WHO announcement includes three new rapid diagnostic tests targeting pf-LDH, not HRP2, because some P. falciparum strains have lost the gene that makes HRP2 and can evade standard rapid tests.
WHO says about 30 million babies are born each year in malaria-endemic areas of Africa; children under five account for roughly three-quarters of malaria deaths in the WHO African Region.
The drug is the obvious headline. The diagnostic change is the structural one: treatment only works if the first-line test still sees the parasite.

What happened

Ahead of World Malaria Day 2026, the World Health Organization prequalified artemether-lumefantrine for newborns and young infants weighing between 2 kg and 5 kg. Prequalification is not merely a press-release badge. It is the mechanism that lets UN agencies, donors and public-sector buyers procure a product at scale because it has passed international quality, safety and efficacy assessment.

Novartis says the product, marketed as Coartem Baby and in some countries Riamet Baby, was developed with Medicines for Malaria Venture and will be made available on a largely not-for-profit basis in malaria-endemic regions. The product is already introduced in Ghana, according to Novartis.

WHO also prequalified three new malaria rapid diagnostic tests on 14 April 2026. These tests are designed for places where the standard HRP2-based tests are losing sensitivity because some parasite strains carry pfhrp2 deletions. WHO says studies and surveys in 46 countries have found these deletions, and that in parts of the Horn of Africa up to 80% of cases can be missed by HRP2-based tests. WHO recommends switching to alternatives where more than 5% of cases are missed because of pfhrp2 deletions.

What it actually means

This is a two-part infrastructure story.

The infant drug closes a product gap. For years, clinicians have had to adapt formulations intended for older children, raising the risk of under-dosing, over-dosing, toxicity and delayed treatment in the smallest patients. That is a bad workaround in any disease. In malaria, it is worse because infants can deteriorate quickly and health systems in high-burden regions often work with thin staffing, limited diagnostics and procurement constraints.

The diagnostic update protects the detection layer. A malaria programme is a chain: test, confirm, treat, monitor, prevent. If the test begins returning false negatives because the parasite has evolved around its target marker, the rest of the chain becomes theatre. A pf-LDH-targeting test is not glamorous, but it is the kind of tool that keeps case management real.

What this is not

This is not proof that malaria is close to elimination. WHO’s own numbers say the opposite: 282 million cases and 610,000 deaths in 2024, with progress stalling under drug resistance, insecticide resistance, diagnostic failure and funding pressure. A new infant formulation does not compensate for collapsing donor budgets. New diagnostics do not distribute themselves.

Who is affected

Ministries of health in malaria-endemic countries now have a procurement-ready option for the 2–5 kg cohort.
Donors and procurement agencies should revise tenders, essential medicines lists and quantification models.
Clinicians and community health workers need updated dosing guidance and referral protocols.
Diagnostic programme leads in the Horn of Africa and other HRP2-deletion zones should not treat this as optional.
Australian-funded Indo-Pacific health programmes should assess relevance for Papua New Guinea, Solomon Islands and Vanuatu, even where the HRP2 deletion pattern differs from Africa.

Recommendations

Global-health procurement teams: add Coartem Baby / Riamet Baby to 2026–27 antimalarial product planning where national guidance permits.
National malaria control programmes: run or update pfhrp2 deletion surveillance. If missed cases exceed WHO’s 5% threshold, plan migration away from exclusive HRP2 testing.
DFAT / Indo-Pacific programme teams: map whether existing malaria grants fund infant case management, diagnostic procurement, or both. The diagnostic line item is the one most likely to be missed.
Implementers: treat training as part of the product. A new formulation without field-level dosing confidence is still a fragile intervention.

Uncertainty ledger

Country-level adoption timelines are not yet clear.
Price, supply reliability and cold-chain or storage constraints need confirmation by procurement channel.
HRP2 deletion prevalence is local. The diagnostic switch should be surveillance-led, not copy-pasted.

Bottom Line

The baby drug matters because it fixes a basic failure: the smallest patients finally get a medicine designed for them. The diagnostic update matters because malaria control collapses when the parasite becomes invisible to the test. The operational call is simple: update procurement for the 2–5 kg cohort, and audit whether your diagnostic stack still sees the disease it claims to detect.

Sources: